vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and BROADWIND, INC. (BWEN). Click either name above to swap in a different company.

Amarin Corp plc is the larger business by last-quarter revenue ($45.1M vs $37.7M, roughly 1.2× BROADWIND, INC.). On growth, BROADWIND, INC. posted the faster year-over-year revenue change (12.4% vs 7.0%). Over the past eight quarters, BROADWIND, INC.'s revenue compounded faster (0.2% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Broadwind Inc. is a U.S.-headquartered industrial manufacturer that produces heavy structural components, gearing systems, and offers aftermarket services for renewable energy, infrastructure, and heavy industrial segments. It primarily supplies core parts for wind turbines, utility energy projects, and industrial equipment to clients across North America.

AMRN vs BWEN — Head-to-Head

Bigger by revenue
AMRN
AMRN
1.2× larger
AMRN
$45.1M
$37.7M
BWEN
Growing faster (revenue YoY)
BWEN
BWEN
+5.4% gap
BWEN
12.4%
7.0%
AMRN
Faster 2-yr revenue CAGR
BWEN
BWEN
Annualised
BWEN
0.2%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRN
AMRN
BWEN
BWEN
Revenue
$45.1M
$37.7M
Net Profit
$-10.5M
Gross Margin
8.8%
Operating Margin
35.5%
-0.2%
Net Margin
-23.3%
Revenue YoY
7.0%
12.4%
Net Profit YoY
33.0%
EPS (diluted)
$-0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
BWEN
BWEN
Q1 26
$45.1M
Q4 25
$49.2M
$37.7M
Q3 25
$49.7M
$44.2M
Q2 25
$72.7M
$39.2M
Q1 25
$42.0M
$36.8M
Q4 24
$62.3M
$33.6M
Q3 24
$42.3M
$35.5M
Q2 24
$67.5M
$36.5M
Net Profit
AMRN
AMRN
BWEN
BWEN
Q1 26
$-10.5M
Q4 25
$-1.2M
Q3 25
$-7.7M
$7.5M
Q2 25
$-14.1M
$-989.0K
Q1 25
$-15.7M
$-370.0K
Q4 24
$-48.6M
Q3 24
$-25.1M
$74.0K
Q2 24
$1.5M
$482.0K
Gross Margin
AMRN
AMRN
BWEN
BWEN
Q1 26
Q4 25
47.1%
8.8%
Q3 25
44.7%
10.2%
Q2 25
69.2%
10.1%
Q1 25
59.8%
11.7%
Q4 24
-15.4%
11.3%
Q3 24
38.5%
14.6%
Q2 24
63.4%
15.3%
Operating Margin
AMRN
AMRN
BWEN
BWEN
Q1 26
35.5%
Q4 25
-12.9%
-0.2%
Q3 25
-22.4%
19.7%
Q2 25
-22.0%
-0.4%
Q1 25
-39.9%
0.5%
Q4 24
-84.3%
-0.9%
Q3 24
-59.5%
3.3%
Q2 24
-0.8%
3.4%
Net Margin
AMRN
AMRN
BWEN
BWEN
Q1 26
-23.3%
Q4 25
-2.5%
Q3 25
-15.6%
16.9%
Q2 25
-19.4%
-2.5%
Q1 25
-37.4%
-1.0%
Q4 24
-78.0%
Q3 24
-59.4%
0.2%
Q2 24
2.3%
1.3%
EPS (diluted)
AMRN
AMRN
BWEN
BWEN
Q1 26
Q4 25
$0.00
$-0.03
Q3 25
$-0.02
$0.32
Q2 25
$-0.03
$-0.04
Q1 25
$-0.04
$-0.02
Q4 24
$-0.12
$-0.04
Q3 24
$-0.06
$0.00
Q2 24
$0.00
$0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
BWEN
BWEN
Cash + ST InvestmentsLiquidity on hand
$307.8M
$456.0K
Total DebtLower is stronger
$10.1M
Stockholders' EquityBook value
$66.3M
Total Assets
$645.8M
$116.8M
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
BWEN
BWEN
Q1 26
$307.8M
Q4 25
$302.6M
$456.0K
Q3 25
$286.6M
$1.2M
Q2 25
$298.7M
$1.0M
Q1 25
$281.8M
$1.2M
Q4 24
$294.2M
$7.7M
Q3 24
$305.7M
$1.4M
Q2 24
$306.7M
$938.0K
Total Debt
AMRN
AMRN
BWEN
BWEN
Q1 26
Q4 25
$10.1M
Q3 25
$10.3M
Q2 25
$26.1M
Q1 25
$12.2M
Q4 24
$9.2M
Q3 24
$16.9M
Q2 24
$18.0M
Stockholders' Equity
AMRN
AMRN
BWEN
BWEN
Q1 26
Q4 25
$459.3M
$66.3M
Q3 25
$458.9M
$66.9M
Q2 25
$464.9M
$59.0M
Q1 25
$473.7M
$59.3M
Q4 24
$486.2M
$59.4M
Q3 24
$531.4M
$59.6M
Q2 24
$551.9M
$59.1M
Total Assets
AMRN
AMRN
BWEN
BWEN
Q1 26
$645.8M
Q4 25
$670.8M
$116.8M
Q3 25
$659.8M
$119.6M
Q2 25
$670.1M
$130.5M
Q1 25
$655.7M
$129.3M
Q4 24
$685.3M
$128.3M
Q3 24
$750.6M
$125.1M
Q2 24
$799.9M
$122.5M
Debt / Equity
AMRN
AMRN
BWEN
BWEN
Q1 26
Q4 25
0.15×
Q3 25
0.15×
Q2 25
0.44×
Q1 25
0.21×
Q4 24
0.15×
Q3 24
0.28×
Q2 24
0.30×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
BWEN
BWEN
Operating Cash FlowLast quarter
$857.0K
Free Cash FlowOCF − Capex
$-187.0K
FCF MarginFCF / Revenue
-0.5%
Capex IntensityCapex / Revenue
2.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-19.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
BWEN
BWEN
Q1 26
Q4 25
$15.3M
$857.0K
Q3 25
$-12.7M
$4.3M
Q2 25
$16.6M
$-12.5M
Q1 25
$-12.5M
$-8.0M
Q4 24
$-13.3M
$14.8M
Q3 24
$-2.4M
$2.4M
Q2 24
$-2.7M
$-9.3M
Free Cash Flow
AMRN
AMRN
BWEN
BWEN
Q1 26
Q4 25
$-187.0K
Q3 25
$3.8M
Q2 25
$-13.7M
Q1 25
$-9.0M
Q4 24
$14.5M
Q3 24
$1.7M
Q2 24
$-10.1M
FCF Margin
AMRN
AMRN
BWEN
BWEN
Q1 26
Q4 25
-0.5%
Q3 25
8.6%
Q2 25
-34.8%
Q1 25
-24.3%
Q4 24
43.1%
Q3 24
4.8%
Q2 24
-27.6%
Capex Intensity
AMRN
AMRN
BWEN
BWEN
Q1 26
Q4 25
2.8%
Q3 25
1.1%
Q2 25
3.1%
Q1 25
2.5%
Q4 24
1.0%
Q3 24
2.1%
Q2 24
2.2%
Cash Conversion
AMRN
AMRN
BWEN
BWEN
Q1 26
Q4 25
Q3 25
0.57×
Q2 25
Q1 25
Q4 24
Q3 24
32.99×
Q2 24
-1.81×
-19.26×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

BWEN
BWEN

Heavy Fabrications$21.6M57%
Industrial Solutions$9.4M25%
Gearing$7.0M19%

Related Comparisons